Ignite Creation Date:
2024-05-05 @ 6:39 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00528411
Status:
COMPLETED
Last Update Posted:
2012-01-13
First Post:
2007-09-10
Brief Title:
A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor Clopidogrel and Placebo With Aspirin
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Multi-centre Randomised Double-blind Double-dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of Ticagrelor Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disease CAD
Status:
COMPLETED
Status Verified Date:
2012-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see how Ticagrelor a new oral reversible anti-platelet medication affects platelets Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of platelets Blood clots prevent us from bleeding but when they form inside the arteries their formation is linked to a risk of medical problems such as heart attack and stroke This study investigated how long it takes for Ticagrelor to begin working and how long it takes for it to stop working after the last dose of drug Ticagrelor will be compared to clopidogrel an established anti-platelet treatment for preventing blood clots and placebo plus Aspirin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None